Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia

about

Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia

Item

http://www.wikidata.org/entity/Q26744365

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@ast

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@en

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@nl

type

Item

label

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@ast

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@en

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@nl

prefLabel

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@ast

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@en

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@nl

P1476

Drugs under preclinical and cl ...... chronic lymphoblastic leukemia

@en

P2093

Baoan Chen

http://www.w3.org/2001/XMLSchema#string

Joe Antony Jacob

http://www.w3.org/2001/XMLSchema#string

Jumah Masoud Mohammad Salmani

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Anti-leukemia activity of a bacterial toxin with natural specificity for LFA-1 on white blood cells.

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.

Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.

Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.

P304

1115-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

659396

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/PPA.S109477

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27382259

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

4920255

http://www.w3.org/2001/XMLSchema#string